Dextech Medical (DEX.SL) Akcja Kurs

Dextech Medical AB develops drug candidates for urological oncology, focusing on prostate cancer and other conditions. The company utilizes its patented GuaDex technology platform to create modified carbohydrate molecules combined with active substances. Its portfolio includes OsteoDex for bone metastases in castration-resistant prostate cancer, SomaDex targeting acromegaly and neuroendocrine tumors, and CatDex for bladder cancer treatment. The company holds patents or patent applications for these three drug candidates. Dextech Medical AB's primary revenue streams come from licensing its technology and drug candidates to pharmaceutical partners. The company's GuaDex platform and its drug candidates, OsteoDex, SomaDex, and CatDex, are marketed to biopharmaceutical companies seeking innovative treatments for urological oncology and related diseases. The firm's focus on prostate cancer, bone metastases, and bladder cancer creates a targeted market for its products. The company's business model relies on developing and commercializing its drug candidates through partnerships with established pharmaceutical companies. With only three drug candidates in its portfolio, Dextech Medical AB targets specific therapeutic areas within urological oncology, leveraging its patented GuaDex platform to attract potential partners in the biopharmaceutical industry.